Overview:
The Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community, an initiative of the American Society of Pharmacovigilance (ASP), is set to host its Annual Meeting and Consensus Workshop from October 23-25, 2024, at the U.S. Pharmacopeia Campus in Rockville, MD. This workshop represents a critical milestone in the ongoing effort to develop and harmonize standards for pharmacogenetics testing, aligning stakeholder perspectives and accelerating the adoption of precision medicine practices as a standard of care.
STRIPE Annual Meeting and Consensus Workshop
Onsite and online, October 23-25, 2024.
Advance registration is required.
About STRIPE:
STRIPE is a continuing forum where public and private sector members collaborate to integrate precision medicine into standard healthcare practices. Convened by the American Society of Pharmacovigilance, STRIPE unites patients, providers, industry leaders, regulators, payers, and other key stakeholders to address complex challenges and achieve common objectives in the field of pharmacogenomics.
Significance of the workshop:
This event is pivotal in fostering collaboration, addressing key challenges, and developing consensus-driven standards for pharmacogenomics. The outcomes of this workshop will significantly impact the future of precision medicine, ensuring that pharmacogenetic testing becomes an integral part of healthcare.
Some of the topics scheduled for discussion:
- Defining Stakeholder Challenges
- Evaluating Evidence Review Processes for Pharmacogenetics Testing
- Ensuring Equity in Pharmacogenomics
- Promulgating Consensus-Driven Standards – What Happens Next?
Event details:
Date: October 23-25, 2024
Location: US Pharmacopeia (USP) Campus, 12601 Twinbrook Pkwy, Rockville, MD or VIRTUAL
Purpose: Develop consensus statements related to pharmacogenetics testing
Cost: $250 onsite or $50 virtual
Format: Panel discussions, consensus workshops, and open discussions
Event Highlights:
- Four panel discussions offering insights from various stakeholder perspectives
- Six consensus workshops for in-depth discussions based on attendee preferences
- Anonymized voting to gather trends in perspectives across health sectors
Encouraged to participate:
Persons/organizations who would be impacted by pharmacogenetic testing standards including Industry, academia, healthcare, patient advocates, regulators, payers, and more, from strong adopters to clinical skeptics.
Contact Information:
- Sara Rogers, PharmD, ASP President (sara@stopadr.org)
- Blaine Groat, PharmD, MS, BCSCP, USP Senior Scientist (blaine.groat@usp.org)